Session » Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

Date: Monday, November 14, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1375

A Five Year Study of 102 Children with Juvenile Myositis: Disease Course and Outcomes

9:00AM-11:00AM: Abstract Number: 1394

A Pilot Study of Consensus Treatment Plans for Induction Therapy in Childhood Proliferative Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1389

Alterations in Nailfold Capillaroscopy in Childhood-Onset Systemic Lupus Erythematosus: The Role of Disease Activity in a Prospective Study

9:00AM-11:00AM: Abstract Number: 1383

ANTI-RO/SSA and/or ANTI-La/SSB Antibodies: Association with Mild LUPUS Manifestations in 645 Childhood-Onset Systemic LUPUS Erythematosus

9:00AM-11:00AM: Abstract Number: 1362

Associations Between 25-Hydroxyvitamin D, Parathyroid Hormone, and Cathelicidin Concentrations with Inflammation and Cardiovascular Risk in Subjects with Pediatric Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1368

Clinical Course of Juvenile Dermatomyositis Presenting As Skin Predominant Disease

9:00AM-11:00AM: Abstract Number: 1396

Cognitive Function in Children with SLE Nephritis: A Cross-Sectional Comparison to Children with Other Glomerular Chronic Kidney Diseases

9:00AM-11:00AM: Abstract Number: 1371

Comparison of Patient and Physician Reported Global Disease Activity Measures in Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1372

Comparison of the Printo 2010 and Printo/International Myositis and Clinical Studies Group (IMACS) 2016 Improvement Criteria in the Printo Trial in New Onset Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1384

Comparison of the Systemic Lupus Collaborating Clinics-Damage Index Score with a Physician Global Assessment of Damage in an International Cohort of Patients with Childhood-Onset Systemic Lupus

9:00AM-11:00AM: Abstract Number: 1397

Correlation and Responsiveness of Cutaneous Lupus Disease Area and Severity Index (CLASI) and Skindex-29 with Cutaneous Childhood Lupus Erythematosus (cSLE)

9:00AM-11:00AM: Abstract Number: 1370

Development and Validation of a Composite Disease Activity Score for Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1388

Distinct Clinical Correlates of Immune Thrombocytopenic Purpura at Diagnosis of Childhood-Onset and Adult SLE

9:00AM-11:00AM: Abstract Number: 1382

Effect of Lupus Anticoagulant on Rotational Thromboelastometry in Juvenile Systemic Lupus Erythematosus: Preliminary Data on a Single Center Cohort

9:00AM-11:00AM: Abstract Number: 1364

Efficacy and Safety of Tumour Necrosis Factor Antagonists in a Large Cohort of Juvenile Dermatomyositis Patients

9:00AM-11:00AM: Abstract Number: 1387

Evaluation of Mild to Moderate SLE Flare in Patients with Childhood-Onset Disease

9:00AM-11:00AM: Abstract Number: 1379

Evaluation of S100 Proteins As Potential Biomarkers of Global and Renal-Specific Disease Activity in Childhood-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1373

Evaluation of the Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and Cutaneous Assessment Tool Binary Method (CAT-BM) in Juvenile Dermatomyositis Among Pediatric Dermatologists, Rheumatologists, and Neurologists

9:00AM-11:00AM: Abstract Number: 1366

Evidence Based Criteria for Corticosteroid Tapering/Discontinuation. an Analysis of the Paediatric Rheumatology International Trials Organization (PRINTO) Trial in New Onset Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1392

Familial Aggregation of Autoimmune Diseases in Childhood and Adulthood Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1369

Features Distinguishing Clinically Hypo- and Amyopathic Juvenile Dermatomyositis (CAJDM) from Juvenile Dermatomyositis (JDM)

9:00AM-11:00AM: Abstract Number: 1385

Frequency of the Systemic Lupus Collaborating Clinics- Damage Index Items in Three Registries of Childhood-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1381

Humoral Immune Response and Cytokine Profile after a Booster Dose with Tdap Vaccine in Juvenile Systemic Lupus Erythematosus and Controls

9:00AM-11:00AM: Abstract Number: 1376

In Juvenile Dermatomyositis, Organ Damage Is Comparable after Median 13.5 and 21.5 Years Follow-up Time, Despite Sustained Disease Activity

9:00AM-11:00AM: Abstract Number: 1367

Long-Term Outcomes and Their Predictors in Patients with Juvenile Idiopathic Inflammatory Myopathies of Adult Age: A Referral Population Study

9:00AM-11:00AM: Abstract Number: 1380

Multicenter Prospective Study on the Role of Urinary HER2 As a Lupus Nephritis Biomarker

9:00AM-11:00AM: Abstract Number: 1393

Mycophenolic Acid Pharmacokinetics in Childhood-Onset Systemic Lupus Erythematosus Patients of Hispanic Ethnicity in a Single Center

9:00AM-11:00AM: Abstract Number: 1391

Novel Electronic Health Record-Based Method Confirms Increased Renal Disease Burden in Pediatric-Onset Vs. Adult-Onset Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1386

Outcome of 847 Childhood-Onset Systemic LUPUS Erythematousus Patients in Three Age Groups

9:00AM-11:00AM: Abstract Number: 1378

Pentraxin-3 Level Predicts Vasculitis and Mucocutaneous Involvement in Childhood-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1398

Practice-Based Differences Between Pediatric Rheumatologists and Dermatologists Caring for Children with Discoid Lupus

9:00AM-11:00AM: Abstract Number: 1374

Predictors of Changes in Disease Activity Among Children with Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1400

Preliminary Validation of the Turkish Simple Measure of Impact of Lupus Erythematosus in Youngsters (SMILEY) in a Single Center

9:00AM-11:00AM: Abstract Number: 1395

Regional Brain Gray Matter Volume Loss in Children and Adolescents with SLE

9:00AM-11:00AM: Abstract Number: 1363

Serum Adipokines in Juvenile Dermatomyositis Are Associated with Disease Activities and Cardiac Function

9:00AM-11:00AM: Abstract Number: 1377

The Role of Muscle MRI in Detecting a Flare-up of Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1361

The Role of Von Willebrand Factor Antigen As a Disease Biomarker in the Clinical Assessment of Children with Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1399

Transitioning Lupus Patients from Pediatric to Adult Rheumatology

9:00AM-11:00AM: Abstract Number: 1365

Trends in Medication Usage in Patients with Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1401

Ultrasonography of Major Salivary Glands in Juvenile SjöGren’s Syndrome − Preliminary Findings in a Multi-Center Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].